Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | RET |
Variant | G810S |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | RET G810S lies within the protein kinase domain of the Ret protein (UniProt.org). G810S has been demonstrated to confer resistance to tyrosine kinase inhibitors in the context of RET fusions (PMID: 29908090, PMID: 31988000), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Jan 2024). |
Associated Drug Resistance | Y |
Category Variants Paths |
RET mutant RET G810S |
Transcript | NM_020975.6 |
gDNA | chr10:g.43119566G>A |
cDNA | c.2428G>A |
Protein | p.G810S |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001406759.1 | chr10:g.43119566G>A | c.2428G>A | p.G810S | RefSeq | GRCh38/hg38 |
NM_001406760.1 | chr10:g.43119566G>A | c.2428G>A | p.G810S | RefSeq | GRCh38/hg38 |
NM_020975.6 | chr10:g.43119566G>A | c.2428G>A | p.G810S | RefSeq | GRCh38/hg38 |
NM_020630.5 | chr10:g.43119566G>A | c.2428G>A | p.G810S | RefSeq | GRCh38/hg38 |
NM_020975 | chr10:g.43119566G>A | c.2428G>A | p.G810S | RefSeq | GRCh38/hg38 |
NM_020975.5 | chr10:g.43119566G>A | c.2428G>A | p.G810S | RefSeq | GRCh38/hg38 |
NM_020630.7 | chr10:g.43119566G>A | c.2428G>A | p.G810S | RefSeq | GRCh38/hg38 |
NM_020630 | chr10:g.43119566G>A | c.2428G>A | p.G810S | RefSeq | GRCh38/hg38 |
NM_001406744.1 | chr10:g.43119566G>A | c.2428G>A | p.G810S | RefSeq | GRCh38/hg38 |
NM_001406743.1 | chr10:g.43119566G>A | c.2428G>A | p.G810S | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET V804M RET G810S RET L881V RET M918T | thyroid gland medullary carcinoma | predicted - resistant | Selpercatinib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with hereditary medullary thyroid carcinoma harboring germline RET M918T demonstrated disease progression following an initial response to Retevmo (selpercatinib), and ctDNA sequencing revealed a decrease in RET L881V, but an increase in RET V804M and RET G810S (PMID: 31988000). | 31988000 |
RET V804M RET G810S RET M918T | Advanced Solid Tumor | resistant | Selpercatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing RET V804M, G810S, and M918T were resistant to Retevmo (selpercatinib) treatment in culture (PMID: 33161056). | 33161056 |
RET V804M RET G810S | Advanced Solid Tumor | predicted - sensitive | TY-1091 | Preclinical - Biochemical | Actionable | In a preclinical study, TY-1091 inhibited activity in a cell line expressing RET G810S and V804M in culture (Cancer Res (2023) 83 (7_Supplement): 3419). | detail... |
RET G810S RET M918T | Advanced Solid Tumor | predicted - sensitive | TY-1091 | Preclinical - Biochemical | Actionable | In a preclinical study, TY-1091 inhibited activity in a cell line expressing RET G810S and M918T in culture (Cancer Res (2023) 83 (7_Supplement): 3419). | detail... |